iZafe Group AB ("iZafe Group") today announces that Ida Almgren has decided to step down as Chief Financial Officer to explore new career opportunities.

During the transition period, Ida will actively assist iZafe Group to ensure a smooth transition, while a search process for a new CFO commences. Ida's last day of work will be June 18.

iZafe is deeply committed to a stable transition and to continuously delivering value to our shareholders and stakeholders. We are fully focused on executing our long-term strategy and realizing our business plans with precision and determination.

iZafe Group AB ("iZafe Group") is pleased to announce the launch of Dosell version 3.0, the latest edition of our revolutionary medication robot, designed to optimize medication management for users worldwide. In connection with this launch, iZafe Group has also initiated a strategic move of its production to Central Europe in order to be able to scale up the production rate to larger volumes and shorten the delivery distances to existing partners.

The first production run of 1,000 pieces of Dosell version 3.0 has been successfully completed and delivered for the Dutch market, marking the starting point for this new and improved version. With, among other things, a more powerful processor and increased memory capacity, Dosell version 3.0 now enables a unified software platform regardless of geographical location or design of the sachet bag. This represents a significant improvement from previous versions that required extensive customization for each individual country and sachet type. In addition, the new version of Dosell 3.0 introduces several advanced features, including voice and expanded connectivity options, further improving the user experience and accessibility.

"The launch of Dosell version 3.0 is an important milestone for us. The new components in this version not only enable a higher and better performance of existing functions, but also open up a wide range of new and innovative functions in the future. All this, without significantly affect the production cost, thanks to the progress made in the component market since Dosell's first version was developed." Says Anders Segerström, CEO of Zafe Group.

This strategic investment in innovation and product development, together with the relocation of production to Central Europe, positions iZafe Group at the forefront of medical technology solutions. With Dosell version 3.0, iZafe Group can now offer an even more reliable and efficient medicine management solution, making it easier for users worldwide to take the right medicine at the right time.

iZafe Group AB ("iZafe Group") announces today that they have received an official order for 1,000 units of Dosell in accordance with the agreement announced on February 27, 2023. These units will be produced as soon as possible and are expected to be delivered to IVE Ventures ("IVE") in February 2024.

Earlier this year, iZafe announced an exclusive partnership with IVE, giving them the sole rights to sell and market Dosell medication robots in the Netherlands. According to this agreement, IVE committed to purchasing a minimum of 1,000 Dosell units each year for a three-year period to retain exclusivity. The total value of hardware purchases and license revenues over the first three years amounts to approximately 16 million SEK, with annual recurring license revenues of at least 6 million SEK thereafter.
 
"We look forward to continuing our partnership with iZafe Group and introducing Dosell to the Dutch market. This order for 1,000 units is a clear demonstration of our dedication to promoting innovative health and healthcare solutions," says Martijn Van Bree, CEO of IVE Ventures.
 
IVE's commitment to improving health and healthcare solutions and their dedication to Dosell is evident through their initial order of 1,000 Dosell units. Their promise to annually purchase at least 1,000 units to maintain exclusivity in the Dutch market reflects their strategic approach to strengthening their portfolio. With extensive experience in providing connected health and healthcare services since 2014, IVE has identified Dosell's potential to enhance and provide a reliable and secure medication solution to their customers in healthcare and alarm services in the Netherlands.

iZafe Group AB ('iZafe Group') announces that the award decision, which was announced on December 8, 2023, where iZafe Group won the procurement with Helsingborg Municipality for the delivery of Dosell medication dispensers, has now led to the city choosing to cancel the process. This decision is motivated by identified shortcomings in the municipality's procurement documents.

The previous press release was published on December 8, 2023, announcing that iZafe Group had won the procurement with a potential value ranging from 5.5 to 13.8 million SEK for 150–400 Dosell medication dispensers. The award decision was not legally binding.
Despite the interruption, iZafe Group remains optimistic and looks forward to showcasing its expertise once the procurement is resumed.

"It is regrettable that the procurement has been interrupted, but we see this as an opportunity to improve and continue our positive dialogue with Helsingborg Municipality. We are ready to participate again when the procurement is expected to resume in January 2024," says Anders Segerström, CEO of iZafe Group.

iZafe Group AB ("iZafe Group") announces that it has been awarded a contract in a procurement with the Municipality of Helsingborg for the provision of iZafe's pharmaceutical dispensers, Dosell. The procurement includes 150-400 units, with an estimated value of SEK 5.5–13.8 million. The contract is owned by Dosell AB, a wholly-owned subsidiary of iZafe Group.

The contract period is two years with the possibility of an additional two-year extension, and the contract will be signed no earlier than 10 days after the award, the time required by procurement rules to elapse before a contract can be signed.
This is merely a decision of award and is not legally binding until a contract has been entered into.

iZafe Group's board member, Bosse Johansson, acquired 800,000 Class B shares in the company yesterday, valued at 216,000 SEK (0.27 SEK per share).

The purchase was made yesterday, on November 30th. Bosse Johansson's total shareholding in iZafe now amounts to these 800,000 Class B shares.

"Acquiring shares in iZafe is a step that demonstrates my confidence in the company's direction and potential. I look forward to continuing to contribute to our collective success and supporting the company's development," says Bosse Johansson.

iZafe Group's CEO, Anders Segerström, presented the company at the Aktiespararna’s event Stora Aktiedagarna on November 29. The presentation was held in Swedish and includes updates on the acquisition of Pilloxa, the significance of winning the procurement in Sweden, and the status of Dosell's existing markets.

You can watch the presentation here.
You can also find this presentation and previous ones here

iZafe Group (publ.) hereby announces that CEO Anders Segerström will present an investor presentation on Wednesday, November 29th at 4:25 PM at the "Stora Aktiedagarna" in Stockholm.

On Wednesday, November 29th at 4:25 PM, iZafe will present its operations at the "Stora Aktiedagarna" in Stockholm. The address is Birger Jarlsgatan 61 A. The presentation will also be broadcast live in Swedish at https://invitepeople.com/public/events/af87c9f59a/pages/aa3d4312cf and will be available afterwards on the Youtube channel of Aktiespararna as well as on iZafe's website.

Questions can be sent via SMS to the number +46(0) 79-347 98 45.
For more information: https://invitepeople.com/events/af87c9f59a

iZafe Group AB ("iZafe Group") announces that the agreement with the Västra Götaland Region (VGR) for the delivery of Dosell medication dispensers has now been concluded. This follows the earlier communication of the award decision and covers 1,800 units, with a maximum of 2,250. The agreement is owned by Atea Sweden AB.

This new agreement, extending until 2025 with the possibility of an extension until 2027, underscores iZafe Group's commitment to enhancing the independence of home care recipients through advanced welfare technology.
 
The framework agreement includes medication robots from Dosell and has an estimated value of SEK 42–52 million. In addition to VGR, 46 municipalities are connected for call-offs under the agreement.
 
"By signing this agreement, we take another important step forward in providing efficient solutions for medication management. Our collaboration with Atea Sweden and the newly signed agreement with VGR marks a milestone for us in the healthcare and welfare technology sector," says Anders Segerström, CEO of iZafe Group.
 
Under the agreement, iZafe Group will supply Dosell medication dispensers to care recipients in VGR, aiming to enhance their independence and safety. "We are proud to contribute to improved healthcare quality and more efficient medication management through our innovative products," Segerström adds.

iZafe Group AB (publ.) is pleased to announce that the company's major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren. This step marks a significant milestone in enhancing corporate governance and ensuring that the company's leadership is aligned with shareholder interests and strategic objectives.

The Nomination Committee comprises the following members, representing a diverse mix of the company's ownership:

  • Patrik Björn, representing personal holdings through Gästrike Nord Invest AB
  • Stefan Wård, representing personal holdings
  • Marc Tarruell Tibau, representing personal holdings through Timedi S.L.
  • Björn Rosengren, Chairman of the Board, iZafe Group AB

Stefan Wård has been appointed as the Chairman of the Nomination Committee.

The Nomination Committee represents approximately 33% of the total number of outstanding shares and votes.

The primary responsibility of the Nomination Committee is to prepare and present proposals for the Annual General Meeting, on May 30 2024, regarding the election of the meeting's chairman, the Board of Directors, the Chairman of the Board, and auditors. The committee will also propose fees for board members and remuneration for auditors.

Shareholders in iZafe Group are encouraged to submit proposals to the Chairman of the Nomination Committee. Submissions can be made via email at or by postal mail to: iZafe Group, Attn: Nomination Committee, David Bagares Gata 3, 111 38 Stockholm, Sweden.

This initiative underscores iZafe Group's commitment to robust corporate governance practices that support the company's long-term strategy and value creation for shareholders.

Webbdesign av Comlog Webbyrå Stockholm